| Aspect | Strongly disagree n (%) | Disagree n (%) | Not sure n (%) | Agree n (%) | Strongly agree n (%) | Mean (SD) | Median |
| Donated blood is free, but there are significant costs associate with blood processing and administration | 5 (3.3) | 1 (0.7) | 7 (4.7) | 55 (36.7) | 82 (54.7) | 4.5 (0.9) | 4.5 |
| As a clinician I understand the risks and costs of allogeneic transfusion, and because of this, I try to minimize the use of BT | 8 (5.3) | 14 (9.3) | 19 (12.7) | 66 (44.0) | 43 (28.7) | 3.8 (1.1) | 4.0 |
| Consent for BT is implied and therefore there is no need to obtain one from the patient | 85 (56.7) | 47 (31.3) | 7 (4.7) | 7 (4.7) | 4 (2.7) | 4.4 (1.0) | 4.5 |
| Presence of fatigue, weakness, dizziness, and pallor is a good indication for a BT | 23 (15.3) | 32 (21.3) | 15 (10.0) | 49 (32.7) | 31 (20.7) | 2.8 (1.4) | 2.6 |
| Formulation and implementation of evidence based clinical practice guidelines reduce variation in blood use by clinicians and promote practices in transfusion medicine | 2 (1.3) | 2 (1.3) | 14 (9.3) | 48 (32.0) | 84 (56.0) | 4.4 (0.8) | 4.5 |
| The availability of blood components, the cost of a transfusion and awareness of transfusion guidelines would influence my transfusion decision | 4 (2.7) | 4 (2.7) | 5 (3.3) | 63 (42.0) | 74 (49.3) | 4.3 (0.9) | 4.5 |
| Compared with red blood cells, platelet transfusions are associated with a lower risk of transmission of diseases; hence I can use platelets without worries | 1 (0.7) | 12 (8.0) | 37 (24.7) | 56 (7.3) | 44 (29.3) | 3.9 (1.0) | 3.9 |
| A patient with chronic kidney disease and a Hb of >8.0 g/dL would make me decide to transfuse blood to patient | 18 (12.0) | 33 (22.0) | 30 (20.0) | 51 (34.0) | 18 (12.0) | 3.1 (1.2) | 3.2 |